Information Provided By:
Fly News Breaks for March 4, 2020
OMER
Mar 4, 2020 | 11:51 EDT
Wedbush analyst Liana Moussatos raised the firm's price target on Omeros to $22 from $18 and keeps a Neutral rating on the shares after the company reported quarterly results earlier this week as well as positive topline data from its Narsoplimab HSCT-TMA clinical trial. Moussatos said she increased her multiple for Narsoplimab HSCT-TMA to 7x from 6x as well. The analyst added that the company ended 2019 with cash, equivalents and short-term investments of $60.8M and that she projects runway into late Q4 of 2020.
News For OMER From the Last 2 Days
There are no results for your query OMER